ANI Pharmaceuticals Inc (NASDAQ:ANIP) Receives $46.00 Consensus Price Target from Brokerages

Share on StockTwits

ANI Pharmaceuticals Inc (NASDAQ:ANIP) has received an average rating of “Hold” from the seven research firms that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $46.00.

ANIP has been the subject of a number of research analyst reports. Zacks Investment Research cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 27th. Raymond James lowered their target price on ANI Pharmaceuticals from $49.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, August 3rd. Finally, BidaskClub cut ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 29th.

In related news, CEO Patrick D. Walsh purchased 10,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $30.78 per share, for a total transaction of $307,800.00. Following the transaction, the chief executive officer now owns 23,096 shares of the company’s stock, valued at approximately $710,894.88. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 24.80% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its stake in ANI Pharmaceuticals by 7.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 62,891 shares of the specialty pharmaceutical company’s stock worth $2,034,000 after buying an additional 4,469 shares during the period. Engineers Gate Manager LP acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth approximately $987,000. Federated Hermes Inc. raised its stake in ANI Pharmaceuticals by 329.6% during the 2nd quarter. Federated Hermes Inc. now owns 300,868 shares of the specialty pharmaceutical company’s stock worth $9,730,000 after buying an additional 230,832 shares during the period. State of Tennessee Treasury Department raised its stake in ANI Pharmaceuticals by 5.5% during the 2nd quarter. State of Tennessee Treasury Department now owns 6,602 shares of the specialty pharmaceutical company’s stock worth $213,000 after buying an additional 345 shares during the period. Finally, American International Group Inc. raised its stake in ANI Pharmaceuticals by 5.7% during the 2nd quarter. American International Group Inc. now owns 6,663 shares of the specialty pharmaceutical company’s stock worth $215,000 after buying an additional 361 shares during the period. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Shares of ANI Pharmaceuticals stock traded down $0.78 during trading on Tuesday, reaching $29.15. 53,901 shares of the company’s stock were exchanged, compared to its average volume of 79,047. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.31 and a current ratio of 1.98. ANI Pharmaceuticals has a 1-year low of $25.23 and a 1-year high of $80.87. The company has a market cap of $358.98 million, a P/E ratio of -17.05 and a beta of 1.30. The firm’s 50-day moving average price is $30.43 and its 200 day moving average price is $36.32.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.12. ANI Pharmaceuticals had a positive return on equity of 20.11% and a negative net margin of 10.27%. The company had revenue of $48.47 million during the quarter, compared to analysts’ expectations of $45.70 million. During the same quarter in the previous year, the firm earned $1.44 EPS. As a group, equities research analysts predict that ANI Pharmaceuticals will post 3 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Recommended Story: Is it Safe to Invest in Commodities?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply